VolitionRX (VNRX) Releases Quarterly Earnings Results, Meets Expectations

VolitionRX (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Wednesday. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.14), Fidelity Earnings reports.

NYSEAMERICAN VNRX opened at $2.70 on Friday. VolitionRX has a 12-month low of $1.44 and a 12-month high of $4.00.

In other VolitionRX news, Director Guy Archibald Innes acquired 50,000 shares of the business’s stock in a transaction on Thursday, August 16th. The stock was purchased at an average price of $2.00 per share, with a total value of $100,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

TRADEMARK VIOLATION NOTICE: This news story was reported by WKRB News and is the property of of WKRB News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/09/volitionrx-vnrx-releases-quarterly-earnings-results-meets-expectations.html.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Read More: Balance Sheet

Earnings History for VolitionRX (NYSEAMERICAN:VNRX)

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply